Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years
Filename | 231. Potter et al, Rupatadine CSU children,PAI2016.pdf |
Filesize | 642.87 KB |
Version | o.231 |
Date added | July 30, 2020 |
Downloaded | 1 time |
Category | Original Work |
Tags | Antihistamine, children, chronic spontaneous urticaria, Quality of life, rupatadine |
Authors | Potter, P., Mitha, E., Barkai, L., Gyorgyl, M., Santamaria, E., Izquierdo, I., and Maurer, M. |
Citation | Potter, P., Mitha, E., Barkai, L., Gyorgyl, M., Santamaria, E., Izquierdo, I., and Maurer, M.: Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr. Allergy Immunol. 2016: 27; 55-61. |
Corresponding authors | Izquierdo, I. |
DocNum | O.231 |
DocType | |
Edition; Page | 27; 55-61 |
IF | 3.77 |
Publisher | Pediatr. Allergy Immunol. |
ReleaseDate | 2016 |
Background: Recommendations in current guidelines for the treatment of chronic spontaneous urticaria (CSU) in infants and children are mostly based on extrapolation of data obtained in adults. This study reports the efficacy and safety of rupatadine, amodern H1and PAF antagonist recently authorized in Europe for children withallergic rhinitis and CSU.
Methods: A double-blind, randomized, parallel-group, multicentre, placebo-controlled compared study to desloratadine was carried out in children aged 2–11 years with CSU, with or without angio-oedema. Patients received either rupatadine (1 mg/ml), ordesloratadine (0.5 mg/ml) or placebo once daily over 6 weeks. A modified 7-daycumulative Urticaria Activity Score (UAS7) was employed as the primary end-point.
Results: The absolute change of UAS7 at 42 days showed statistically significant differences between active treatments vs. placebo (5.57.5 placebo,11.88.7 rupatadine and10.69.6 desloratadine; p<0.001) and without differences between antihistamines compounds. There was a 55.8% decrease for rupatadinefollowed by desloratadine (48.4%) and placebo (30.3%). Rupatadine but notdesloratadine was statistically superior to placebo in reduction of pruritus (57%). Active treatments also showed a statistically better improvement in children’s qualityof life compared to placebo. Adverse events were uncommon and non-serious in bothactive groups.
Conclusion: Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU. This is the firststudy using a modified UAS to assess severity and efficacy outcome in CSU in children.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.